NCT06621823 Image-guided Ultrasound Robotic Intraoperative Evaluation of Lymph-nodes Status in Gynecological Malignancies
| NCT ID | NCT06621823 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Fondazione Policlinico Universitario Agostino Gemelli IRCCS |
| Condition | Lymph Node Metastasis |
| Study Type | INTERVENTIONAL |
| Enrollment | 160 participants |
| Start Date | 2024-07-25 |
| Primary Completion | 2025-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 160 participants in total. It began in 2024-07-25 with a primary completion date of 2025-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The assessment of lymph node status is of crucial importance in gynaecological malignancies. Indeed, the prognosis and adjuvant treatment regimens are strongly influenced by the presence of nodal involvement. Systematic extensive lymphadenectomies are often performed for staging, diagnosis of skip metastases and to define the radiation field when radiotherapy treatments are required. Nevertheless, these can lead to significant short-term and long-term lymphatic complications, which are difficult to justify if the lymph nodes are free from metastasis. To avoid unnecessary comprehensive procedures in early-stage cancers, evaluation of the sentinel lymph node has acquired a valuable role even if limitations are still present (rate of frozen section false negative, "empty packets" and mapping failure). The introduction of an intra-operative non-invasive imaging technique capable of describing the presence and characteristics of lymph nodes could help in (1) eliminating the risk of empty packet, (2) orienting the intraoperative decision while avoiding the drawbacks of frozen section (time and resources, partial destruction of the tissue material), (3) orientate the pathological section if frozen section is used. To date, technological advancements have paved the way for enhanced intra-operative assessment of cancerous organs and lesions. Over the past decade, the evolution of robotic surgery combined with advancements in image-guided surgery techniques has led to the introduction of ultrasound probes designed specifically for intraoperative ultrasound during robotic surgery (RIOUS). Apart from the conventional rigid laparoscopic probes, which can be inserted through an accessory trocar, there are robotic probes tailored to fit device arms, and drop-in flexible probes that are becoming increasingly relevant in the scientific panorama. Notably, the latter drop-in probes feature a rigid segment designed for compatibility with robotic graspers, leveraging the dexterity and rotational manoeuvrability inherent to robotic surgery. Such probes, already proven effective in evaluating liver and kidney lesions as well as tumour margins, hold promise for intraoperative lymph node assessments due to the possibility of reaching difficult anatomical spaces thanks to the robotic-assisted movements
Eligibility Criteria
Inclusion Criteria: * Women undergoing robotic surgery for gynecological malignancies (ovarian, endometrial, cervical cencers) * Need for nodal excision (staging or cytoreductive reasons) * 18-99 years old * Absence of contemporary lymphatic diseases * Absence of previous oncological disease in the last 5 years * Willingness to participate in the study and to provide informed consent Exclusion Criteria: * \- Previous radiotherapy treatments in the area of analysed lymph nodes * Previous chemotherapy treatments
Contact & Investigator
Antonia Carla Testa, Professor
PRINCIPAL INVESTIGATOR
Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome
Frequently Asked Questions
Who can join the NCT06621823 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 99 Years, studying Lymph Node Metastasis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06621823 currently recruiting?
Yes, NCT06621823 is actively recruiting participants. Contact the research team at antoniacarla.testa@policlinicogemelli.it for enrollment information.
Where is the NCT06621823 trial being conducted?
This trial is being conducted at Roma, Italy.
Who is sponsoring the NCT06621823 clinical trial?
NCT06621823 is sponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCS. The principal investigator is Antonia Carla Testa, Professor at Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome. The trial plans to enroll 160 participants.